



1632
Atty Dkt No. 029996-0278721
Pat. App. Ser. No. 09/804,409

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re PATENT APPLICATION OF

Kieffer et al.

Group Art Unit: 1632

Appln. No.: 09/804,409

Examiner: P. Paras, Jr.

Filed: March 12, 2001


(RCE Filed: June 16, 2004)

Title: COMPOSITIONS AND METHODS FOR REGULATED PROTEIN EXPRESSION
IN GUT

TRANSMITTAL LETTER

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing Under 37 C.F.R. §1.8
I hereby certify that this correspondence along with any paper referred
to as being attached is being Mailed to Addressee by service of the
United States Postal Service addressed to Commissioner for Patents,
P.O. Box, 1450, Alexandria, VA 22313-1450

Date: August 18, 2004 By: 

Sachiko Y. Snedden

Sir:

Transmitted herewith for filing are the following:

1. Information Disclosure Statement;
2. PTO Form 1449;
3. Cited References (8);
4. Copy of International Search Report (04/18/2002); and
5. Return Postcard.


No fee is incurred for filing this Statement. However, the Commissioner is hereby authorized to charge any fee that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment to Deposit Account 50-2212, Order No. 029996-0278721. A duplicate of this Transmittal is enclosed.

Respectfully submitted,

Pillsbury Winthrop LLP

Date: August 18, 2004

11682 El Camino Real, Suite 200
San Diego, CA 92130-2092
(619) 234-5000

By: 
Robert M. Bedgood, Ph.D.
Reg. No. 43,488
Tel. No. (858) 509-4065
Fax No. (858) 509-4010



Atty Dkt No. 029996-0278721
Pat. App. Ser. No. 09/804,409

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Kieffer et al.

Group Art Unit: 1632

Serial No.: 09/804,409

Examiner: P. Paras, Jr.

Filed: March 12, 2001

Title:

(RCE Filed: June 16, 2004)

COMPOSITIONS AND METHODS FOR
REGULATED PROTEIN EXPRESSION IN
GUT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Attached is Form PTO-1449 listing the enclosed cited references in this statement.

Contingent Request Under Rule 97(c): Should a first action on the merits have been issued on the same day or before this Information Disclosure Statement is filed, please accept this Information Disclosure Statement under Rule 97(c) and charge the requisite Rule 17(p) fee to our Deposit Account No. 50-2212, under the above Atty Dkt. No., and proceed to consider this Information Disclosure Statement.

Certificate of Mailing Under 37 C.F.R. §1.8

I hereby certify that this correspondence along with any paper referred to as being attached is being Mailed to Addressee by service of the United States Postal Service addressed to Commissioner for Patents, P.O. Box, 1450, Alexandria, VA 22313-1450

By: _____

Sachiko Y. Snedden

Date: August 18, 2004

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

This Information Disclosure Statement is not to be constructed as a representation that any of the listed citations establishes, by itself or in combination with other information, a prima facie case of unpatentability of any claim in the above-identified patent application. Additionally, this Information Disclosure Statement is not to be constructed as a representation that a further search of the art has been made by the Applicant, or that additional information unknown to the Applicant and relevant to the examination of this patent application does not exist.

Consideration of the foregoing and enclosures plus the return of a copy of the enclosed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 are earnestly solicited along with an early action on the merits.


No fee is incurred for filing this Statement. However, the Commissioner is hereby authorized to charge any fee, that may be due in connection with this and the attached papers, or with this application during its entire pendency, or to credit any overpayment, to Deposit Account No. 50-2212, Order No. 029996-0278721.

Respectfully submitted,

Pillsbury Winthrop LLP

Date: August 18, 2004

By


Robert M. Bedgood, Ph.D.
Reg. No. 43,488

11682 El Camino Real
Suite 200
San Diego, CA 92130-2092
(619) 234-5000

Tel. No. (858) 509-4065
Fax No. (858) 509-4010

Client Ref.

Applicant: Kieffer et al.

Appln. No.: 09/804,409

Filing Date: March 12, 2001

Examiner: P. Paras, Jr.

Art Unit: 1632

Date: August 18, 2004

Page

1

lot

2

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Date Considered:

***EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty.
Dkt. No.

C-

Client Ref.

029996-0278721

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Kieffer et al.

Appln. No.: 09/804,409

Filing Date: March 12, 2001

Date: August 18, 2004

Page

2

of

2

Examiner: P. Paras, Jr.

Art Unit: 1632

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

Examiner's Initials*			English Abstract		Translation Readily Available	
			Enclosed	No	Enclosed	No
	DR	Welsh; Gene Therapy in Diabetes Mellitus: Promises and Pitfalls; Current Opinion in Molecular Therapeutics, vol. 1, no. 4; 1999; pp. 464-470				
	ER	Mizuno et al.; Successful Culture and Sustainability <i>in Vivo</i> of Gene-Modified Human Oral Mucosal Epithelium; Human Gene Therapy, vol. 10; March 1999; pp. 825-830				
	FR	Mitanech et al; Regulated Expression of Mature Human Insulin in the Liver of Transgenic Mice; FEBS Letters, vol. 421; 1998; pp. 285-289				
	GR	Lee et al.; Remission in Models of Type 1 Diabetes by Gene Therapy Using a Single-Chain Insulin Analogue; Nature, vol. 408; November 2000; pp. 483-488				
	HR	Mitanech et al.; Glucose-Stimulated Genes and Prospects of Gene Therapy for Type I Diabetes; Endocrine Reviews, vol. 18, no. 4; 1997; pp. 520-540				

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.